Numerous studies are researching the possible effects of different kinase inhibitors in single or combination therapies (NCT04620330), to assess the efficacy of VS-6766 (a dual RAF/MEK inhibitor) as a monotherapy or in combination with defactinib in NSCLC patients with recurrency [3,58]. Here, RAF1 is linked to non-small cell lung carcinoma.